Intra-Cellular Therapies Stock - consensus and analyst view mid-year

Intra-Cellular Therapies enters mid-2026 with its schizophrenia and bipolar depression drugs shaping analyst expectations. With no fresh corporate headlines today, the focus turns to earnings consensus, rating distribution and how the stock fits into the biotech peer group.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 17:30 UTC. Details in the imprint.

Intra-Cellular Therapies (US46116X1019) develops central nervous system drugs including Caplyta for schizophrenia and bipolar depression. With no new filings or major news today from the company or top wire services, the focus shifts to the analyst consensus and how the stock is currently valued against those expectations.

What analysts currently expect

Without a fresh earnings release or regulatory update today, investor attention turns to the earnings and revenue consensus compiled over recent weeks for Intra-Cellular Therapies stock. Sell-side models broadly assume continued growth in Caplyta prescriptions in schizophrenia and bipolar depression, but the level of profitability and cash burn remains a central debate for the mid-2020s investment case.

Across the sector, biotech analysts typically track year-ahead revenue, adjusted loss or profit per share and cash runway as key metrics. For a commercial-stage CNS player like Intra-Cellular Therapies, the balance of investment in further indications versus the path to sustainable profitability tends to drive rating dispersion more than near-term quarterly noise.

How ratings and consensus shape the view

On a consensus basis, Wall Street generally frames Intra-Cellular Therapies as a growth story tied to the uptake trajectory of Caplyta and potential pipeline expansion in mood and psychotic disorders. Some broker models emphasize the addressable market in bipolar depression and the potential for broader use in maintenance treatment, while others highlight execution and reimbursement risks that could cap upside.

Rating distributions in such mid-cap biotech names typically span from Buy recommendations anchored in robust prescription trends to more cautious Neutral stances where valuation already prices in ambitious growth scenarios. Target prices set by the analyst community usually reference discounted cash flow scenarios for Caplyta and assign varying option value to earlier-stage assets.

The product behind the stock

Intra-Cellular Therapies generates its revenue primarily from Caplyta, an antipsychotic medicine approved in the US for the treatment of schizophrenia and depressive episodes associated with bipolar I and II disorder in adults. The company is also working on additional central nervous system indications and pipeline candidates that could diversify its revenue base over time.

Where the stock trades today

The shares of Intra-Cellular Therapies (US46116X1019) trade on Nasdaq in US dollars; the latest available quote and market capitalization can be obtained directly from the Nasdaq data pages or the company’s investor relations site.

Intra-Cellular Therapies at a glance

• Company: Intra-Cellular Therapies Inc.
• ISIN: US46116X1019
• Ticker: ITCI
• Venue: Nasdaq

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.